Integra LifeSciences has received the CE Mark and is launching its Integra Flowable Wound Matrix for treating deep soft tissue or tunneling wounds common in diabetic foot and leg ulcers. The product, made of granulated cross-linked bovine tendon collagen and glycosaminoglycan, is based on Integra’s wound matrix and has already been used in the U.S. for a number of years.
The material is first mixed with saline to hydrate it and it can then be injected into wound sites to create a scaffold within which healthy tissue can grow.
Features from the product page:
- Gel-like consistency allows intimate contact between the grafting material and wound bed
- Composition and method of administration allows for complete coverage in deep creviced wounds
- Provides a resorbable scaffold onwhich cells can attach, migrate, proliferate and differentiate
- Designed with a pore structure that permits cells to migrate into the matrix, allowing them the opportunity to populate and effectively remodel the matrix
Product page: INTEGRA™ Flowable Wound Matrix…
Press release: Integra LifeSciences Announces Launch of Integra(R) Flowable Wound Matrix in Europe for Diabetic Foot and Leg Ulcers
